Test Bank for Julien's Primer of Drug Action, 15th Edition By Robert M. Julien, Claire D. Advokat, and Joseph E. Comaty Complete Exam Practice Questions and Answers ABOUT THIS TEST BANK This document provides exam practice questions and answers

Test Bank for Julien's Primer of Drug Action, 15th Edition By Robert M. Julien, Claire D. Advokat, and Joseph E. Comaty Complete Exam Practice Questions and Answers ABOUT THIS TEST BANK This document provides exam practice questions and answers for the 15th Edition of Julien's Primer of Drug Action by Robert M. Julien, Claire D. Advokat, and Joseph E. Comaty. Textbook Information: Full Title: Julien's Primer of Drug Action: A Comprehensive Guide to the Actions, Uses, and Side Effects of Psychoactive Drugs Edition: 15th Authors: Robert M. Julien, Claire D. Advokat, Joseph E. Comaty Publisher: Macmillan Learning Publication Date: 2023 ISBN: 9781319244866 (Paperback) TEXTBOOK TABLE OF CONTENTS Part Title Chapters Part 1 Introduction to Psychopharmacology: The Biological Basis of Drug Action 1-3 Part 2 Pharmacology of Drugs of Abuse 4-10 Part 3 Psychotherapeutic Drugs 11-14 Part 4 Special Populations 15-18 Chapter Listing: Chapter 1: Pharmacokinetics: How the Body Handles Drugs Chapter 2: Brain, Neurons, Synaptic Transmission, and Neurotransmitters Chapter 3: Pharmacodynamics: How Drugs Act Chapter 4: Addiction: Terminology, Epidemiology, Neurobiology, and Pharmacology Chapter 5: Ethyl Alcohol and the Inhalants of Abuse Chapter 6: Caffeine and Nicotine Chapter 7: Psychostimulants: Cocaine, Amphetamines, and Nonamphetamines Chapter 8: Psychedelic Drugs Chapter 9: Cannabis Chapter 10: Opioids Chapter 11: Antipsychotic Drugs Chapter 12: Antidepressant Drugs Chapter 13: Sedative-Hypnotic Drugs: Treatment of Anxiety, Insomnia, and Epilepsy; Induction of Anesthesia Chapter 14: Drugs Used to Treat Bipolar Disorder Chapter 15: Pregnancy and Psychoactive Drugs Chapter 16: Child and Adolescent Psychopharmacology Chapter 17: Geriatric Psychopharmacology Chapter 18: Challenging Times for Mental Health: The COVID-19 Pandemic and Beyond SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS Question 1 A drug is defined as: A) Any chemical substance that can be purchased over the counter B) A biologically active substance that can modify cellular function C) A substance that only treats diseases D) Any substance that is harmful to the body Answer: B) A biologically active substance that can modify cellular function Rationale: A drug is defined as a biologically active substance that can modify cellular function. This broad definition encompasses both therapeutic and recreational drugs. Question 2 The three terms used to measure drug response or action are: A) Absorption, distribution, metabolism B) Dose-response curve, potency, and efficacy C) Agonist, antagonist, partial agonist D) Tolerance, dependence, withdrawal Answer: B) Dose-response curve, potency, and efficacy Rationale: The three key measures of drug response are dose-response curve (relationship between drug concentration and effect), potency (amount needed to produce an effect), and efficacy (maximum intensity of effect a drug can produce). Question 3 Potency refers to: A) The maximum effect a drug can produce B) The amount of drug needed to produce an effect C) The speed at which a drug takes effect D) The duration of a drug's action Answer: B) The amount of drug needed to produce an effect Rationale: Potency is related to the amount of drug needed to produce an effect. A more potent drug requires a lower dose to achieve the same effect as a less potent drug. Question 4 Efficacy refers to: A) The amount of drug needed to produce an effect B) The maximum intensity of effect or response that can be produced by a drug C) The rate at which a drug is eliminated from the body D) The binding affinity of a drug to its receptor Answer: B) The maximum intensity of effect or response that can be produced by a drug Rationale: Efficacy is the maximum intensity of effect or response that can be produced by a drug, regardless of the dose required to achieve that effect. Question 5 The therapeutic index (TI) is calculated as: A) ED50 / LD50 B) LD50 / ED50 C) ED50 × LD50 D) LD50 - ED50 Answer: B) LD50 / ED50 Rationale: The therapeutic index is the ratio of the median lethal dose (LD50) to the median effective dose (ED50). The greater the TI, the safer the drug. Question 6 Drugs with a lower therapeutic index (closer to zero) require: A) Less careful monitoring B) Careful monitoring to avoid toxic reactions C) Higher doses to be effective D) No special precautions Answer: B) Careful monitoring to avoid toxic reactions Rationale: Drugs with a lower therapeutic index (closer to zero) have a narrow margin of safety and require careful monitoring to avoid toxic reactions. Question 7 For a drug to exert its effects, it must: A) Be absorbed into the bloodstream B) Bind with the receptor site on the cell membrane C) Be metabolized by the liver D) Cross the blood-brain barrier Answer: B) Bind with the receptor site on the cell membrane Rationale: For a drug to exert its effects, it must bind with the receptor site on the cell membrane. This binding initiates the cellular response that produces the drug's effects. Question 8 Drugs with ________ affinities for receptor sites are more potent than drugs with weaker affinities for the same sites. A) Weaker B) Stronger C) Equal D) Variable Answer: B) Stronger Rationale: Drugs with stronger affinities for receptor sites are more potent than drugs with weaker affinities for the same sites, as they bind more readily and effectively to their molecular targets. Question 9 An agonist is a drug that: A) Blocks receptor activation B) Has affinity for a receptor, combines with the receptor, and produces an effect C) Has no effect on receptors D) Only works on peripheral receptors Answer: B) Has affinity for a receptor, combines with the receptor, and produces an effect Rationale: An agonist is a drug that has affinity for a receptor, combines with the receptor, and produces an effect. Naturally occurring neurotransmitters are examples of agonists. Question 10 An antagonist is a drug that: A) Produces the same effect as an agonist B) Counteracts the action of the agonist C) Has no affinity for receptors D) Only works on peripheral receptors Answer: B) Counteracts the action of the agonist Rationale: An antagonist counteracts the action of the agonist. It may have affinity for the receptor but produces no effect, thereby blocking the agonist from binding and activating the receptor. Question 11 Lipid-soluble substances move across the lipoprotein membrane by a passive transfer process called: A) Active transport B) Facilitated diffusion C) Simple diffusion D) Endocytosis Answer: C) Simple diffusion Rationale: Lipid-soluble substances move across the lipoprotein membrane by a passive transfer process called simple diffusion. This process is directly proportional to the concentration gradient of the drug across the membrane and the degree of lipid solubility. Question 12 Absorption is the process by which: A) Drug molecules are metabolized in the liver B) Drug molecules are transferred from the site of administration to the circulating blood C) Drug molecules bind to receptors D) Drug molecules are eliminated from the body Answer: B) Drug molecules are transferred from the site of administration to the circulating blood Rationale: Absorption is the process by which drug molecules are transferred from the site of administration to the circulating blood and requires the drug to pass through biologic membranes. Question 13 The factors that influence the rate of absorption of a drug include: A) The site of absorption and the drug's solubility B) The patient's age only C) The drug's color D) The time of day Answer: A) The site of absorption and the drug's solubility Rationale: The factors that influence the rate of absorption of a drug include the site of absorption (determined by the route of administration) and the drug's solubility (drugs in solution are more rapidly absorbed than insoluble drugs). Question 14 The first-pass effect refers to: A) The first dose of a medication B) The liver inactivating some drugs before they reach systemic circulation C) The initial binding of a drug to its receptor D) The first sign of drug action Answer: B) The liver inactivating some drugs before they reach systemic circulation Rationale: The first-pass effect occurs when the liver inactivates some drugs, reducing the amount that reaches systemic circulation. Due to this effect, the dose required when given orally is higher than the dose needed when used parenterally. Question 15 Morphine has a: A) Low first-pass effect B) High first-pass effect C) No first-pass effect D) Variable first-pass effect Answer: B) High first-pass effect Rationale: Morphine has a high first-pass effect, meaning that a significant portion is metabolized by the liver before reaching systemic circulation when taken orally. Question 16 The half-life (t½) of a drug is: A) The time it takes for the drug to reach peak concentration B) The amount of time that passes for its concentration to fall to half (50%) of its original blood level C) The time required for complete elimination of the drug D) The time between doses Answer: B) The amount of time that passes for its concentration to fall to half (50%) of its original blood level Rationale: The half-life (t½) of a drug is the amount of time that passes for its concentration to fall to half (50%) of its original blood level. It takes approximately 4-5 half-lives for a drug to be considered eliminated from the body. Question 17 With zero-order kinetics: A) The rate of metabolism increases with dose B) The rate of metabolism remains constant over time, and the same amount of drug is metabolized per unit of time regardless of dose C) The drug is eliminated faster at higher doses D) The drug is excreted unchanged Answer: B) The rate of metabolism remains constant over time, and the same amount of drug is metabolized per unit of time regardless of dose Rationale: With zero-order kinetics, the rate of metabolism remains constant over time, and the same amount of drug is metabolized per unit of time regardless of dose. Alcohol is an example of a drug that exhibits zero-order kinetics. SECTION 2: NEUROBIOLOGY AND BRAIN STRUCTURE Question 18 The three primary divisions of the brain are: A) Cerebrum, cerebellum, brainstem B) Hindbrain, midbrain, and forebrain C) Cortex, thalamus, hypothalamus D) Gray matter, white matter, ventricles Answer: B) Hindbrain, midbrain, and forebrain Rationale: The three primary divisions of the brain are the hindbrain, the midbrain, and the forebrain. Question 19 The cerebellum is a structure necessary for: A) Memory formation B) Emotion regulation C) The proper integration of movement and posture D) Language processing Answer: C) The proper integration of movement and posture Rationale: The cerebellum is a structure necessary for the proper integration of movement and posture. Loss of coordination and balance due to cerebellar dysfunction is called ataxia. Question 20 The substantia nigra, located in the midbrain, is associated with: A) Memory formation B) The reward circuit C) The coordination of movement and motor control D) Autonomic nervous system integration Answer: C) The coordination of movement and motor control Rationale: The substantia nigra is associated with the neuroanatomical system called the basal ganglia, which is responsible for coordination of movement and integration of motor control. The neurons in this area contain the neurotransmitter dopamine. Question 21 The ventral tegmental area (VTA) is part of: A) The motor control system B) The reward circuit located in the limbic system C) The visual processing system D) The auditory processing system Answer: B) The reward circuit located in the limbic system Rationale: The ventral tegmental area (VTA) is part of the neuroanatomical system called the reward circuit, located in the limbic system. Like the substantia nigra, its neurons contain dopamine. Question 22 The hypothalamus is responsible for: A) Coordination of movement B) Integration of the entire autonomic nervous system C) Processing of sensory information D) Higher-level cognitive functions Answer: B) Integration of the entire autonomic nervous system Rationale: The hypothalamus has 11 major nuclei that are responsible for the integration of our entire autonomic nervous system. It produces releasing factors that travel to the pituitary gland to induce hormone secretion. Question 23 The thalamus functions as: A) The center for emotion and memory B) A way station where all sensory information passes through (except olfactory) C) The primary motor control center D) The site of higher cognitive functions Answer: B) A way station where all sensory information passes through (except olfactory) Rationale: The thalamus is a way station as all sensory information passes through it (except the sense of smell/olfactory). It consists of two lobes on either side of the midbrain, located above the hypothalamus. Question 24 The limbic system is responsible for: A) Movement coordination B) Memory (hippocampus) and emotion (amygdala) C) Sensory perception D) Autonomic regulation Answer: B) Memory (hippocampus) and emotion (amygdala) Rationale: The limbic system is responsible for memory (via the hippocampus) and emotion (via the amygdala). These are critical functions for survival and behavioral responses. Question 25 Parkinson's disease is associated with: A) Excessive dopamine activity B) Gradual loss of the ability to initiate movement C) Unintentional movement D) Loss of memory Answer: B) Gradual loss of the ability to initiate movement Rationale: Parkinson's disease is associated with the gradual loss of ability to initiate movement. This is contrasted with Huntington's disease, which involves the inability to prevent the body from moving unintentionally. SECTION 3: RECEPTORS AND DRUG ACTION Question 26 The two types of drug actions are: A) Agonist and antagonist B) Specific and nonspecific actions C) Therapeutic and toxic D) Central and peripheral Answer: B) Specific and nonspecific actions Rationale: The two types of drug actions are specific and nonspecific actions. Specific actions involve binding to receptors, while nonspecific actions do not involve specific receptor binding. Question 27 Receptors are: A) The sites where drugs are metabolized B) Molecular targets for most drugs that can bind at a recognition site to create a drug-receptor complex C) Proteins that eliminate drugs from the body D) Structures that only respond to neurotransmitters Answer: B) Molecular targets for most drugs that can bind at a recognition site to create a drug-receptor complex Rationale: Receptors are molecular targets for most drugs that can bind at a recognition site to create a drug-receptor complex to produce a physiological response. The recognition site is located on the cell membrane. Question 28 The three main targets for drug action include: A) DNA, RNA, and ribosomes B) Ion channels, enzymes, and carrier proteins C) Mitochondria, nucleus, and cell membrane D) Hormones, neurotransmitters, and cytokines Answer: B) Ion channels, enzymes, and carrier proteins Rationale: The main targets for drug action are specific macromolecules and proteins, including ion channels, enzymes, and carrier proteins. Question 29 Aspirin functions as a drug by: A) Activating dopamine receptors B) Blocking the cyclooxygenase enzyme, inhibiting the formation of prostaglandins C) Binding to opioid receptors D) Inhibiting sodium channels Answer: B) Blocking the cyclooxygenase enzyme, inhibiting the formation of prostaglandins Rationale: Aspirin blocks the cyclooxygenase enzyme, inhibiting the formation of prostaglandins. This explains its anti-inflammatory, analgesic, and antipyretic effects. Question 30 Selective agonists differ from selective antagonists in that: A) Agonists block receptors while antagonists activate them B) Selective agonists activate specific receptors, while selective antagonists block receptor activation C) Agonists are only used for pain while antagonists are used for anxiety D) There is no difference between them Answer: B) Selective agonists activate specific receptors, while selective antagonists block receptor activation Rationale: Selective agonists activate specific receptors, while selective antagonists block receptor activation. This specificity allows for targeted therapeutic effects. Question 31 A full agonist produces: A) Less than the maximum response B) A maximum response C) No response D) The opposite response of an agonist Answer: B) A maximum response Rationale: A full agonist produces a maximum response, such as morphine producing maximal analgesic effect at therapeutic doses. Question 32 A partial agonist produces: A) The maximum response B) Less than the maximum response C) No response at all D) An inverse response Answer: B) Less than the maximum response Rationale: A partial agonist produces less than the maximum response, even when all receptors are occupied. This can be advantageous in situations where full activation would cause unwanted side effects. SECTION 4: DRUGS OF ABUSE Question 33 In the 1930s, which substance was used to treat ADHD? A) Methylphenidate (Ritalin) B) Amphetamines C) Cocaine D) Caffeine Answer: B) Amphetamines Rationale: In the 1930s, amphetamines were used to treat ADHD. Today, methylphenidate (Ritalin) and other stimulants are the drug class of choice for treating ADHD. Question 34 The drug class of choice for treating ADHD is: A) Sedatives B) Methylphenidates and other stimulants C) SSRIs D) Anticonvulsants Answer: B) Methylphenidates and other stimulants Rationale: The drug class of choice for treating ADHD is methylphenidates and other stimulants. These medications increase dopamine and norepinephrine levels in the brain to improve attention and reduce hyperactivity. Question 35 Adolescents use which substance more than any other drug? A) Alcohol B) Nicotine C) Cannabis D) Stimulants Answer: C) Cannabis Rationale: Adolescents use cannabis more than any other drug. This has significant public health implications for brain development and mental health. Question 36 The drug class of choice for treating aggressive disorders in children and adolescents is: A) Sedatives B) Stimulants C) Atypical antipsychotics D) Antidepressants Answer: C) Atypical antipsychotics Rationale: The drug class of choice for treating aggressive disorders in children and adolescents is atypical antipsychotics. These medications help reduce impulsive and aggressive behaviors. SECTION 5: PSYCHOTHERAPEUTIC DRUGS Question 37 For treating schizophrenia spectrum disorders in children and adolescents, which medication had the best safety/coverage ratio? A) Ziprasidone B) Lurasidone C) Aripiprazole D) Olanzapine Answer: C) Aripiprazole Rationale: For treating schizophrenia spectrum disorders in children and adolescents, aripiprazole had the best safety/coverage ratio, indicating a favorable balance between therapeutic efficacy and adverse effects. Question 38 At the cellular level, the biological basis for Parkinsonism is best described as a _____ state. A) Hypernoradrenergic B) Hyponoradrenergic C) Hyperdopaminergic D) Hypodopaminergic Answer: D) Hypodopaminergic Rationale: At the cellular level, the biological basis for Parkinsonism is best described as a hypodopaminergic state—a deficiency of dopamine in the basal ganglia. This explains the motor symptoms of bradykinesia, rigidity, and tremor. Question 39 The clinical syndrome of Parkinsonism includes all of the following EXCEPT: A) Slowness/poverty of movement B) Muscle rigidity C) Tremor during voluntary movement D) Impaired postural balance Answer: C) Tremor during voluntary movement Rationale: The clinical syndrome of Parkinsonism includes slowness/poverty of movement (bradykinesia), muscle rigidity, impaired postural balance, and resting tremor. The tremor in Parkinson's is typically present at rest and diminishes with voluntary movement (unlike cerebellar tremor). Question 40 Levodi oxyphenylalanine (L-DOPA) is a precursor drug to: A) Dopamine B) Dopa decarboxylase C) Tyramine D) Tyrosine Answer: A) Dopamine Rationale: L-DOPA is the precursor to dopamine. It is used in the treatment of Parkinson's disease because it crosses the blood-brain barrier and is converted to dopamine, compensating for the dopamine deficiency in the basal ganglia. Question 41 The mainstay of therapy for Parkinson's disease is: A) Implementation of dopamine neurons B) Administration of dopamine C) Administration of neuroleptics D) Administration of dopamine precursors Answer: D) Administration of dopamine precursors Rationale: The mainstay of therapy for Parkinson's disease is the administration of dopamine precursors, specifically levodopa (L-DOPA) combined with carbidopa. This approach increases dopamine levels in the brain. Question 42 Memantine's mechanism of action is: A) Blockade of acetylcholine receptors B) Inhibition of acetylcholine breakdown C) Blockade of NMDA receptors D) Inhibition of glutamate breakdown Answer: C) Blockade of NMDA receptors Rationale: Memantine's mechanism of action is blockade of NMDA receptors. It is used in the treatment of moderate to severe Alzheimer's disease to regulate glutamate activity. Question 43 The second most common neurodegenerative disease is: A) Alzheimer's disease B) Parkinson's disease C) Depression D) Bipolar disorder Answer: B) Parkinson's disease Rationale: The second most common neurodegenerative disease is Parkinson's disease, after Alzheimer's disease. It affects approximately 1-2% of people over 60 years of age. Question 44 Acetylcholinesterase inhibitors are used to treat _____ in an attempt to address _____ symptoms. A) Alzheimer's disease; cognitive B) Alzheimer's disease; motor C) Parkinson's disease; cognitive D) Parkinson's disease; motor Answer: A) Alzheimer's disease; cognitive Rationale: Acetylcholinesterase inhibitors are used to treat Alzheimer's disease in an attempt to address cognitive symptoms. These drugs increase acetylcholine levels in the brain by preventing its breakdown. Question 45 _____ cause significant cognitive impairment in older adults. A) SSRI antidepressants B) Atypical antipsychotics C) Ritalin D) Benzodiazepines Answer: D) Benzodiazepines Rationale: Benzodiazepines cause significant cognitive impairment in older adults, including memory problems, confusion, and increased fall risk. They should be used with caution in geriatric populations. SECTION 6: PHARMACOKINETICS IN-DEPTH Question 46 The process of drug metabolism that transforms a drug to a more active, equally active, or inactive metabolite is called: A) Absorption B) Distribution C) Biotransformation D) Excretion Answer: C) Biotransformation Rationale: Biotransformation is the process of drug metabolism in the body that transforms a drug to a more active, equally active, or inactive metabolite. This primarily occurs in the liver. Question 47 P450 enzymes are: A) Enzymes that break down drugs in the liver B) Enzymes that synthesize neurotransmitters C) Enzymes that transport drugs across membranes D) Enzymes that protect the blood-brain barrier Answer: A) Enzymes that break down drugs in the liver Rationale: P450 enzymes (cytochrome P450) are enzymes that break down drugs in the liver. They are responsible for the metabolism of numerous drugs and can be induced or inhibited by other substances. Question 48 Drug clearance is defined as: A) The time it takes for a drug to reach peak concentration B) The rate of elimination of a drug from the body C) The amount of drug that binds to plasma proteins D) The percentage of drug that reaches systemic circulation Answer: B) The rate of elimination of a drug from the body Rationale: Drug clearance is the rate of elimination of a drug from the body. It determines the maintenance dose required to achieve a desired steady-state concentration. Question 49 In Phase I reactions, lipid-soluble molecules are metabolized by which three processes that require very little energy? A) Absorption, distribution, elimination B) Oxidation, reduction, and hydrolysis C) Synthesis, storage, release D) Agonism, antagonism, partial agonism Answer: B) Oxidation, reduction, and hydrolysis Rationale: In Phase I reactions, lipid-soluble molecules are metabolized by oxidation, reduction, and hydrolysis processes that require very little energy. These reactions typically introduce or unmask a functional group. Question 50 Elimination of substances through the kidney can occur by three routes: A) Simple diffusion, facilitated diffusion, active transport B) Oxidation, reduction, hydrolysis C) Glomerular filtration, active tubular secretion, and passive tubular diffusion D) Absorption, distribution, metabolism Answer: C) Glomerular filtration, active tubular secretion, and passive tubular diffusion Rationale: Elimination of substances through the kidney can occur by glomerular filtration, active tubular secretion, and passive tubular diffusion. Each route contributes to the overall renal clearance of drugs. Question 51 When the tubular urinary pH is more alkaline than the plasma: A) Weak acids are excreted more slowly and weak bases are excreted more rapidly B) Weak acids are excreted more rapidly and weak bases are excreted more slowly C) Both weak acids and weak bases are excreted more slowly D) Both weak acids and weak bases are excreted more rapidly Answer: B) Weak acids are excreted more rapidly and weak bases are excreted more slowly Rationale: When the tubular urinary pH is more alkaline than the plasma, weak acids are excreted more rapidly and weak bases are excreted more slowly. This principle of "ion trapping" has clinical implications for drug overdoses and urinary alkalinization therapy. Question 52 Other ways drugs can be excreted from the body include: A) Only through feces B) Only through sweat C) Saliva, sweat, breast milk, and gingival crevicular fluid (GCF) D) Only through urine and feces Answer: C) Saliva, sweat, breast milk, and gingival crevicular fluid (GCF) Rationale: Other ways drugs can be excreted include saliva, sweat, breast milk, and gingival crevicular fluid (GCF). These routes may have clinical significance for specific drugs or patient populations.